Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women.
OBJECTIVE
To investigate the effects of dehydroepiandrosterone (DHEA) combined with exercise on bone mass, strength, and physical function in older, frail women.


METHODS
Double-blind, randomized, placebo-controlled trial.


METHODS
A major medical institution.


METHODS
Ninety-nine women (mean age 76.6 ± 6.0) with low sulfated DHEA (DHEAS) levels, low bone mass, and frailty.


METHODS
Participants received 50 mg/d DHEA or placebo for 6 months; all received calcium and cholecalciferol. Women participated in 90-minute twice-weekly exercise regimens.


METHODS
Hormone levels, bone mineral density (BMD), bone turnover markers, body composition, upper and lower extremity strength, physical performance.


RESULTS
Eighty-seven women (88%) completed 6 months. There were no significant changes in BMD or bone turnover markers. DHEA supplementation resulted in gains in lower extremity strength (from 459 ± 121 N to 484 ± 147 N; P=.01). There was also improvement in Short Physical Performance Battery score, a composite score that focuses on lower extremity function, in those taking DHEA (from 10.1 ± 1.8 to 10.7 ± 1.9; P=.02). There were significant changes in all hormone levels, including DHEAS, estradiol, estrone, and testosterone, and a decline in sex hormone-binding globulin levels in those taking DHEA.


CONCLUSIONS
DHEA supplementation improved lower extremity strength and function in older, frail women involved in a gentle exercise program of chair aerobics or yoga. No changes were found in BMD either due to small sample size, short duration of study or no effect. The physical function findings are promising and require further evaluation as frail women are at high risk for falls and fracture.
Kenny
Anne M
AM
Center on Aging, University of Connecticut Health Center, Farmington, Connecticut, USA. kenny@uchc.edu
Boxer
Rebecca S
RS
Kleppinger
Alison
A
Brindisi
Jennifer
J
Feinn
Richard
R
Burleson
Joseph A
JA
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000284:Administration, Oral; D000368:Aged; D015519:Bone Density / Q000187:drug effects; D003687:Dehydroepiandrosterone / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005081:Exercise Therapy / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D016330:Frail Elderly; D006801:Humans; D007866:Leg / Q000502:physiology; D009043:Motor Activity / Q000187:drug effects*; D053580:Muscle Strength / Q000187:drug effects*; D010024:Osteoporosis / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D011379:Prognosis; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism
D000276:Adjuvants, Immunologic; D012738:Sex Hormone-Binding Globulin; D003687:Dehydroepiandrosterone